E-Mail
Following the Food and Drug Administration s approval, UC San Diego Health is the first designated medical center in San Diego certified to offer a new immunotherapy treatment of multiple myeloma outside of a clinical trial.
The new immunotherapy is a B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T-cell therapy, and UC San Diego Health is preparing to treat its first patient this month.
Multiple myeloma is a cancer of blood plasma cells in which the body s T-cells and B-cells become cancerous and multiply. According to the National Cancer Institute, nearly 35,000 Americans will be diagnosed with multiple myeloma in 2021, and treatment options are limited.